Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 517 to 523 of 523 entries
Sorted by: Best Match Show Resources per page
Identification of Sarcopenia in Elderly Trauma Patients: The Value of Clinical Competency and Experience.

The American surgeon

Proksch DM, Kelley KM, White S, Burgess JR.
PMID: 33775105
Am Surg. 2021 Mar 27;3134820982854. doi: 10.1177/0003134820982854. Epub 2021 Mar 27.

INTRODUCTION: There is currently no standard definition of sarcopenia, which has often been associated with frailty. A commonly cited surrogate measure of sarcopenia is psoas muscle size. The purpose of this prospective study is to assess medical providers' capabilities...

Cite
Proksch DM, Kelley KM, White S, et al. Identification of Sarcopenia in Elderly Trauma Patients: The Value of Clinical Competency and Experience. Am Surg. 2021;3134820982854doi: 10.1177/0003134820982854.
Proksch, D. M., Kelley, K. M., White, S., & Burgess, J. R. (2021). Identification of Sarcopenia in Elderly Trauma Patients: The Value of Clinical Competency and Experience. The American surgeon, 3134820982854. https://doi.org/10.1177/0003134820982854
Proksch, Daisy M, et al. "Identification of Sarcopenia in Elderly Trauma Patients: The Value of Clinical Competency and Experience." The American surgeon vol. (2021): 3134820982854. doi: https://doi.org/10.1177/0003134820982854
Proksch DM, Kelley KM, White S, Burgess JR. Identification of Sarcopenia in Elderly Trauma Patients: The Value of Clinical Competency and Experience. Am Surg. 2021 Mar 27;3134820982854. doi: 10.1177/0003134820982854. Epub 2021 Mar 27. PMID: 33775105.
Copy Download .nbib Format: NLM
Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer.

Growth factors (Chur, Switzerland)

Foroughi S, Hutchinson RA, Wong HL, Christie M, Batrouney A, Wong R, Lee M, Tie J, Burgess AW, Gibbs P.
PMID: 33775193
Growth Factors. 2020 Jun-Jul;38(3):127-136. doi: 10.1080/08977194.2021.1878166. Epub 2021 Mar 27.

For patients with metastatic colorectal cancer (mCRC), epidermal growth factor receptor (EGFR) inhibitors are limited to patients with

Cite
Foroughi S, Hutchinson RA, Wong HL, et al. Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. Growth Factors. 2021;38(3):127-136doi: 10.1080/08977194.2021.1878166.
Foroughi, S., Hutchinson, R. A., Wong, H. L., Christie, M., Batrouney, A., Wong, R., Lee, M., Tie, J., Burgess, A. W., & Gibbs, P. (2020). Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. Growth factors (Chur, Switzerland), 38(3), 127-136. https://doi.org/10.1080/08977194.2021.1878166
Foroughi, Siavash, et al. "Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer." Growth factors (Chur, Switzerland) vol. 38,3 (2020): 127-136. doi: https://doi.org/10.1080/08977194.2021.1878166
Foroughi S, Hutchinson RA, Wong HL, Christie M, Batrouney A, Wong R, Lee M, Tie J, Burgess AW, Gibbs P. Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. Growth Factors. 2020 Jun-Jul;38(3):127-136. doi: 10.1080/08977194.2021.1878166. Epub 2021 Mar 27. PMID: 33775193.
Copy Download .nbib Format: NLM
Strategies for extended lifetime of implantable intraperitoneal insulin catheters.

Journal of controlled release : official journal of the Controlled Release Society

He J, Renard E, Lord P, Cohen D, Gu B, Wang X, Yenduri G, Burgess DJ.
PMID: 34856228
J Control Release. 2021 Nov 29;341:487-497. doi: 10.1016/j.jconrel.2021.11.038. Epub 2021 Nov 29.

Implantable insulin infusion systems using the intra-peritoneal route have dramatically changed the management of diabetes paving the way toward the realization of the potential "holy grail" of a fully implantable artificial pancreas. However, the wear duration of delivery catheters...

Cite
He J, Renard E, Lord P, et al. Strategies for extended lifetime of implantable intraperitoneal insulin catheters. J Control Release. 2021;341:487-497doi: 10.1016/j.jconrel.2021.11.038.
He, J., Renard, E., Lord, P., Cohen, D., Gu, B., Wang, X., Yenduri, G., & Burgess, D. J. (2021). Strategies for extended lifetime of implantable intraperitoneal insulin catheters. Journal of controlled release : official journal of the Controlled Release Society, 341487-497. https://doi.org/10.1016/j.jconrel.2021.11.038
He, Jia, et al. "Strategies for extended lifetime of implantable intraperitoneal insulin catheters." Journal of controlled release : official journal of the Controlled Release Society vol. 341 (2021): 487-497. doi: https://doi.org/10.1016/j.jconrel.2021.11.038
He J, Renard E, Lord P, Cohen D, Gu B, Wang X, Yenduri G, Burgess DJ. Strategies for extended lifetime of implantable intraperitoneal insulin catheters. J Control Release. 2021 Nov 29;341:487-497. doi: 10.1016/j.jconrel.2021.11.038. Epub 2021 Nov 29. PMID: 34856228.
Copy Download .nbib Format: NLM
Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants.

Contemporary clinical trials

Coleman BC, Purcell N, Geda M, Luther SL, Peduzzi P, Kerns RD, Seal KH, Burgess DJ, Rosen MI, Sellinger J, Salsbury SA, Gelman H, Brandt CA, Edwards RR.
PMID: 34775101
Contemp Clin Trials. 2021 Dec;111:106619. doi: 10.1016/j.cct.2021.106619. Epub 2021 Nov 12.

Characterizing the impacts of disruption attributable to the COVID-19 pandemic on clinical research is important, especially in pain research where psychological, social, and economic stressors attributable to the COVID-19 pandemic may greatly impact treatment effects. The National Institutes of...

Cite
Coleman BC, Purcell N, Geda M, et al. Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants. Contemp Clin Trials. 2021;111:106619doi: 10.1016/j.cct.2021.106619.
Coleman, B. C., Purcell, N., Geda, M., Luther, S. L., Peduzzi, P., Kerns, R. D., Seal, K. H., Burgess, D. J., Rosen, M. I., Sellinger, J., Salsbury, S. A., Gelman, H., Brandt, C. A., & Edwards, R. R. (2021). Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants. Contemporary clinical trials, 111106619. https://doi.org/10.1016/j.cct.2021.106619
Coleman, Brian C, et al. "Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants." Contemporary clinical trials vol. 111 (2021): 106619. doi: https://doi.org/10.1016/j.cct.2021.106619
Coleman BC, Purcell N, Geda M, Luther SL, Peduzzi P, Kerns RD, Seal KH, Burgess DJ, Rosen MI, Sellinger J, Salsbury SA, Gelman H, Brandt CA, Edwards RR. Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants. Contemp Clin Trials. 2021 Dec;111:106619. doi: 10.1016/j.cct.2021.106619. Epub 2021 Nov 12. PMID: 34775101; PMCID: PMC8585559.
Copy Download .nbib Format: NLM
Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1.

Cell death & disease

Low JT, Ho GY, Scott M, Tan CW, Whitehead L, Barber K, Yip HYK, Dekkers JF, Hirokawa Y, Silke J, Burgess AW, Strasser A, Putoczki TL, O'Reilly LA.
PMID: 34789734
Cell Death Dis. 2021 Nov 17;12(12):1091. doi: 10.1038/s41419-021-04376-2.

No abstract available.

Cite
Low JT, Ho GY, Scott M, et al. Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1. Cell Death Dis. 2021;12(12):1091doi: 10.1038/s41419-021-04376-2.
Low, J. T., Ho, G. Y., Scott, M., Tan, C. W., Whitehead, L., Barber, K., Yip, H. Y. K., Dekkers, J. F., Hirokawa, Y., Silke, J., Burgess, A. W., Strasser, A., Putoczki, T. L., & O'Reilly, L. A. (2021). Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1. Cell death & disease, 12(12), 1091. https://doi.org/10.1038/s41419-021-04376-2
Low, Jun T, et al. "Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1." Cell death & disease vol. 12,12 (2021): 1091. doi: https://doi.org/10.1038/s41419-021-04376-2
Low JT, Ho GY, Scott M, Tan CW, Whitehead L, Barber K, Yip HYK, Dekkers JF, Hirokawa Y, Silke J, Burgess AW, Strasser A, Putoczki TL, O'Reilly LA. Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1. Cell Death Dis. 2021 Nov 17;12(12):1091. doi: 10.1038/s41419-021-04376-2. PMID: 34789734; PMCID: PMC8599488.
Copy Download .nbib Format: NLM
Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants.

Contemporary clinical trials

Coleman BC, Purcell N, Geda M, Luther SL, Peduzzi P, Kerns RD, Seal KH, Burgess DJ, Rosen MI, Sellinger J, Salsbury SA, Gelman H, Brandt CA, Edwards RR.
PMID: 34775101
Contemp Clin Trials. 2021 Dec;111:106619. doi: 10.1016/j.cct.2021.106619. Epub 2021 Nov 12.

Characterizing the impacts of disruption attributable to the COVID-19 pandemic on clinical research is important, especially in pain research where psychological, social, and economic stressors attributable to the COVID-19 pandemic may greatly impact treatment effects. The National Institutes of...

Cite
Coleman BC, Purcell N, Geda M, et al. Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants. Contemp Clin Trials. 2021;111:106619doi: 10.1016/j.cct.2021.106619.
Coleman, B. C., Purcell, N., Geda, M., Luther, S. L., Peduzzi, P., Kerns, R. D., Seal, K. H., Burgess, D. J., Rosen, M. I., Sellinger, J., Salsbury, S. A., Gelman, H., Brandt, C. A., & Edwards, R. R. (2021). Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants. Contemporary clinical trials, 111106619. https://doi.org/10.1016/j.cct.2021.106619
Coleman, Brian C, et al. "Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants." Contemporary clinical trials vol. 111 (2021): 106619. doi: https://doi.org/10.1016/j.cct.2021.106619
Coleman BC, Purcell N, Geda M, Luther SL, Peduzzi P, Kerns RD, Seal KH, Burgess DJ, Rosen MI, Sellinger J, Salsbury SA, Gelman H, Brandt CA, Edwards RR. Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants. Contemp Clin Trials. 2021 Dec;111:106619. doi: 10.1016/j.cct.2021.106619. Epub 2021 Nov 12. PMID: 34775101; PMCID: PMC8585559.
Copy Download .nbib Format: NLM
Does Stereotype Threat Affect Women in Academic Medicine?.

Carnes M, Burgess DJ, Joseph A, van Ryn M.
UIID-AD: 1269
2012;87:506-512. doi: 10.1097/ACM.0b013e318248f718.

Multiple complex factors contribute to the slow pace of women’s advancement into leadership positions in academic medicine. In this article, the authors propose that stereotype threat—under which individuals who are members of a group characterized by negative stereotypes in...

Cite
Carnes M, Burgess DJ, Joseph A, et al. Does Stereotype Threat Affect Women in Academic Medicine?. 2012;87:506-512doi: 10.1097/ACM.0b013e318248f718.
Carnes, M., Burgess, D. J., Joseph, A., & van Ryn, M. (2012). Does Stereotype Threat Affect Women in Academic Medicine?. 87506-512. https://doi.org/10.1097/ACM.0b013e318248f718
Carnes, M, et al. "Does Stereotype Threat Affect Women in Academic Medicine?." vol. 87 (2012): 506-512. doi: https://doi.org/10.1097/ACM.0b013e318248f718
Carnes M, Burgess DJ, Joseph A, van Ryn M. Does Stereotype Threat Affect Women in Academic Medicine?. 2012;87:506-512. doi: 10.1097/ACM.0b013e318248f718. UIID-AD: 1269.
Copy Download .nbib Format: NLM
Showing 517 to 523 of 523 entries